Search results for "Intraperitoneal injection"

showing 10 items of 42 documents

Pharmakologisch-aktive polymere, 18. Körperverteilung und ausscheidungsverhalten von monomerem und polymerem sulfadiazinacrylamid

1979

Sulfadiazinacrylamid was absorbed after oral and intraperitoneal application in rats to a high extent; the absorption from the intraperitoneum was retarded. Glucose treatment delayed the absorption after both application forms. At comparatively high renal and enteral excretion rates the biological half life time of the monomer was estimated to 8 h. A tumouraffinity was not found but there were indications for a preferred storage in the RES. Poly[sulfadiazinacrylamide] was absorbed after intraperitoneal injection to a clear extent, where at the beginning of the treatment under simultaneous glucose load the absorption was delayed. 24 h after injection higher concentrations in metabolic organs…

Excretionchemistry.chemical_compoundMonomerchemistrymedicine.medical_treatmentPolymer chemistryIntraperitoneal injectionmedicineBiological half-lifeAbsorption (skin)Enteral administrationAfter treatmentResorptionDie Makromolekulare Chemie
researchProduct

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

2013

International audience; BACKGROUND: Lipids A, the lipophilic partial structure of lipopolysaccharides, induce regression of several tumor types in animal models. Rather than exerting direct cytotoxic effect, these compounds trigger the immune system which in turn stimulates secretion of cytokines, and activates the inducible nitric oxide synthase, as well as immune cell infiltration of tumors. OM-174 is an analogue of lipid A with dual action on toll-like receptors 2 and 4. In an experimental model of peritoneal carcinomatosis induced in BDIX rats by intraperitoneal injection of syngeneic PROb colon cancer cells, it induced a complete regression of tumors. The present phase I trial was cond…

LipopolysaccharidesMaleCancer Researchmedicine.medical_treatmentPharmacologyRefractory solid tumors[ SDV.CAN ] Life Sciences [q-bio]/CancerOM-1740302 clinical medicineNeoplasmsLipid A analogue0303 health sciencesMiddle Aged3. Good healthKiller Cells NaturalTreatment OutcomeCytokineOncology030220 oncology & carcinogenesisVomitingCytokinesFemaleChillsmedicine.symptomResearch ArticleAdultMaximum Tolerated DoseDoseIntraperitoneal injectionAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerDrug Administration Schedule03 medical and health sciencesImmune systemPhase IPharmacokinetics[SDV.CAN] Life Sciences [q-bio]/CancerCell Line TumormedicineGeneticsAnimalsHumansImmune responseAged030304 developmental biologyChemotherapyPolymorphism Geneticbusiness.industryRatsToll-Like Receptor 4Disease Models Animalbusiness
researchProduct

Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2

1995

AbstractTo explore the functional role of TIMP-2 in liver, we determined TIMP-2 mRNA levels in primary rat hepatocytes and in total rat liver. Rat hepatocytes constitutively express TIMP-2 mRNA at a low level. Incubation with dexamethasone, prostaglandin E2 and a combination of inflammatory cytokines leads to an up-regulation of TIMP-2 mRNA. In rats in vivo we found a dramatic increase of TIMP-2 expression after intraperitoneal injection of lipopolysaccharide. Compared to our previous findings on TIMP-1 we conclude that TIMP-2 mRNA expression is regulated in a distinct and partially opposite manner. Over-production of TIMP-2 could inhibit the activity of metalloproteinases and thus lead to …

Lipopolysaccharidesmedicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentInflammatory mediatorIntraperitoneal injectionBiophysicsTissue inhibitor of metalloproteinaseMatrix metalloproteinaseBiochemistryDexamethasoneDinoprostoneCell LineProinflammatory cytokineMicechemistry.chemical_compoundStructural BiologyFibrosisIn vivoInternal medicineGeneticsmedicineAnimalsHumansRNA MessengerProstaglandin E2Molecular BiologyCells CulturedTissue Inhibitor of Metalloproteinase-2ChemistryMetalloendopeptidasesProteinsExtracellular matrixCell BiologyTissue inhibitor of metalloproteinasemedicine.diseaseFibrosisRatsEndocrinologyGene Expression RegulationLiverProtein BiosynthesisCytokinesRat hepatocytemedicine.drug
researchProduct

Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hyd…

2020

Background: Rapid-acting antidepressants ketamine and (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) have overcome some of the major limitations of classical antidepressants. However, little is known about sex-specific differences in the behavioral and molecular effects of ketamine and (2R,6R)-HNK in rodents. Methods: We treated mice with an intraperitoneal injection of either saline, ketamine (30 mg kg&minus

Male0301 basic medicineHydroxynorketaminemedicine.medical_treatmentAntidepressantAnxietyHippocampuslcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5Salineactivated neuronsSpectroscopyNeuronsRecombination GeneticSex CharacteristicsBehavior AnimalhydroxynorketamineGeneral MedicineComputer Science ApplicationsActivated neuronsAntidepressantFemaleKetaminemedicine.drugmedicine.medical_specialtyketamineMemory Episodicsex differenceGreen Fluorescent ProteinsIntraperitoneal injectionMice TransgenicIn situ hybridizationBiologyHydroxynorketamineArticleCatalysisInorganic Chemistry03 medical and health sciencesInternal medicineketamine ; sex difference ; activated neurons ; antidepressant ; behavior ; BDNF ; rapid-acting ; hydroxynorketaminemedicineAnimalsKetamineRapid-actingPhysical and Theoretical ChemistrySocial BehaviorMolecular BiologyCell NucleusBehaviorantidepressantbehaviorBrain-Derived Neurotrophic FactorOrganic ChemistrySex differencerapid-actingSexual dimorphismDisease Models AnimalBDNF030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999030217 neurology & neurosurgeryBehavioural despair test
researchProduct

In vivo and in vitro antioxidant properties of furosemide

2003

The aim of this study was to investigate in vivo and in vitro antioxidant properties of furosemide. In vitro, human red blood cells were submitted to oxidative stress (AAPH), in absence or in presence of different concentrations of furosemide. Potassium efflux was measured in order to quantify the oxidative stress after the action of AAPH on red blood cells. Allophycocyanin assay was also used to investigate antioxidant capacities of furosemide. For the in vivo experiment, male Wistar rats were used. A control group (n = 5) was treated by a daily intraperitoneal injection of saline solution (0.2 ml); 2 other groups (J0 and J+) were treated for 7 days by one daily intraperitoneal injection o…

MaleErythrocytesAntioxidantmedicine.medical_treatmentIntraperitoneal injectionAmidinesOxidative phosphorylationIn Vitro TechniquesPharmacologymedicine.disease_causeAntioxidantsGeneral Biochemistry Genetics and Molecular BiologyFurosemideIn vivomedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsDiureticsSalineChemistryPhycocyaninFurosemideFree Radical ScavengersGeneral MedicineIn vitroRatsOxidative StressAnesthesiaPotassiumOxidative stressmedicine.drugLife Sciences
researchProduct

l-[3H]lysine binding to rat retinal membrane: II. effect of kainic acid,d,l-?-aminoadipic acid, iodoacetic acid, and modification by dark-exposure

1986

The rat retina and the different brain regions contain membranes sites that bindl-lysine in the nanomolar range. These binding sites undergo changes in different experimental conditions, thus: I) intraocular injection of kainic acid induces a reduction of the density ofl-lysine binding sites, II)d,l-α-aminoadipic acid injected into the eye enhances both kinetic parameters (Bmax andKd) ofl-[3H]lysine binding sites, III) the intraperitoneal injection of iodoacetic acid decreases the sensitivity for its ligand binding sites, and IV) the exposure to darkness of the rats reducesl-[3H]lysine binding in the retina, thalamus, hypothalamus and superior colliculus, but not in the occipital cortex; su…

MaleKainic acidgenetic structuresIodoacetic acidmedicine.medical_treatmentIntraperitoneal injectionLysineIodoacetates2-Aminoadipic AcidBiologycomplex mixturesBiochemistryRetinaCellular and Molecular Neurosciencechemistry.chemical_compoundmedicineAnimalsVisual PathwaysBinding siteKainic AcidLysineBrainRetinalGeneral MedicineDarknessAmino Acids DicarboxylicIodoacetic AcidRatsKineticschemistryBiochemistryDarknessBiophysicsbacteriasense organs2-Aminoadipic AcidNeurochemical Research
researchProduct

Experimental autoimmune hepatitis: Disease induction, time course and t-cell reactivity

1990

This study describes a murine model of autoimmune hepatitis: experimental autoimmune hepatitis. Experimental autoimmune hepatitis could be induced most effectively in male C57BL/6 mice by intraperitoneal immunization with the 100,000 g supernatant of syngeneic liver homogenate (S-100) in complete Freund's adjuvant. BALB/C and C3H mice were less susceptible than C57BL/6 mice. Experimental autoimmune hepatitis could not be induced in Lewis rats. Intraperitoneal immunization was more effective than intramuscular or subcutaneous injections, and the amount of protein administered above a threshold was of little influence. A single intraperitoneal injection of S-100 in complete Freund's adjuvant …

MalePathologymedicine.medical_specialtyTime FactorsNecrosisT-Lymphocytesmedicine.medical_treatmentFreund's AdjuvantIntraperitoneal injectionAutoimmune hepatitisLymphocyte ActivationAutoimmune DiseasesHepatitisPathogenesisMiceNecrosisSpecies SpecificitymedicineAnimalsAutoimmune diseaseHepatitisMice Inbred BALB CMice Inbred C3HHepatologybusiness.industryLiver cellS100 Proteinsmedicine.diseaseMice Inbred C57BLLiverFreund's adjuvantImmunologyFemalemedicine.symptombusinessHepatology
researchProduct

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity

2017

Background Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy. Design and methods Healthy rats were randomized into groups: epirubicin (8 mg/kg) delivered intraperitoneally via micro osmotic pumps (MOP), epirubicin (8 mg/kg) by intraperitoneal (IP) bolus injection, and placebo control. Blood samples were collected for analyzing biomarkers of myocardial injury and pharmacokinetics. At chosen times, sub-groups of animals were sacrificed for histopathology. A mo…

MalePhysiologyCancer Treatmentlcsh:Medicine030204 cardiovascular system & hematologyPharmacologyBiochemistryRats Sprague-DawleyMice0302 clinical medicineBolus (medicine)Intraperitoneal InjectionsBreast TumorsMedicine and Health Scienceslcsh:Scienceskin and connective tissue diseasesInfusions IntravenousRoutes of AdministrationMultidisciplinaryAntibiotics AntineoplasticArea under the curveHeartAnimal ModelsBody FluidsBloodExperimental Organism SystemsOncology030220 oncology & carcinogenesisAnatomyEpirubicinmedicine.drugResearch ArticleAnthracyclineMouse ModelsResearch and Analysis MethodsBlood Plasma03 medical and health sciencesModel OrganismsPharmacokineticsIn vivoCell Line TumorBreast CancermedicineAnimalsDoxorubicinPharmacokineticsAnimal Models of DiseaseEpirubicinPharmacologyCardiotoxicitybusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRatsAnimal Studieslcsh:QbusinessBiomarkersPLoS ONE
researchProduct

Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying

2002

A single intraperitoneal injection of endotoxin (40 μg/kg) significantly delayed gastric emptying of a solid nutrient meal. Blockade of nitric oxide synthase (NOS) with 30 mg/kg ip N G-nitro-l-arginine methyl ester or 20 mg/kg ip 7-nitroindazole [neuronal NOS (nNOS) inhibitor] significantly delayed gastric emptying in control animals but failed to modify gastric emptying in endotoxin-treated rats. Administration of 2.5, 5, and 10 mg/kg ip N 6-iminoethyl-l-lysine [inducible NOS (iNOS) inhibitor] had no effect in either experimental group. Indomethacin (5 mg/kg sc), NS-398 (cyclooxygenase-2 inhibitor; 10 mg/kg ip), and dexamethasone (10 mg/kg sc) but not quinacrine (20 mg/kg ip) significantl…

MalePhysiologymedicine.medical_treatmentIndomethacinNitric Oxide Synthase Type IINitric Oxide Synthase Type IprostaglandinsRats Sprague-Dawleychemistry.chemical_compoundPyloric AntrumEnzyme InhibitorsAntrumSulfonamidesArachidonic AcidbiologyReverse Transcriptase Polymerase Chain ReactionStomachdigestive oral and skin physiologyGastroenterologyNitric oxide synthasemedicine.anatomical_structureNG-Nitroarginine Methyl EsterQuinacrinenutrient mealsantrum. pylorusmedicine.medical_specialtyIndazolesIntraperitoneal injectionNitric OxidePhospholipases ANitric oxidenitric oxidePhysiology (medical)Internal medicinemedicineAnimalsCyclooxygenase InhibitorsRNA MessengerNitrobenzenesHepatologyGastric emptyingPylorusdigestive system diseasesRatsEndotoxinsEndocrinologyPyloric AntrumchemistryGastric EmptyingFoodbiology.proteinProstaglandinsNitric Oxide Synthase
researchProduct

Ajuga ivaaqueous extract improves reverse cholesterol transport in streptozotocin-induced diabetic rat

2012

AbstractObjectivesThe aim of this study was to determine the effects of Ajuga iva aqueous extract on lecithin : cholesterol acyltransferase (LCAT) activity and amount and composition of high-density lipoprotein (HDL)2 and (HDL)3, in streptozotocin (STZ)-induced diabetic rats.MethodsDiabetes was induced in male Wistar rats by intraperitoneal injection of STZ (60 mg/kg body weight). Diabetic rats (n = 12) were divided into two groups. The diabetic control group (D) received a 20% casein diet and the diabetic treated group received the same diet supplemented with A. iva aqueous extract (0.5 g/100 g diet) (DAi), for 4 weeks.Key findingsTotal cholesterol and HDL3-C were respectively decreased by…

Malemedicine.medical_specialtyApolipoprotein Bmedicine.medical_treatmentIntraperitoneal injectionPharmaceutical ScienceAjugaAjugaDiabetes Mellitus ExperimentalPhosphatidylcholine-Sterol O-AcyltransferaseInternal medicineDiabetes mellitusLecithinsmedicineAnimalsRats WistarPhospholipidsTriglyceridesPharmacologyApolipoprotein A-IbiologyPlant ExtractsChemistryCholesterol HDLReverse cholesterol transportBiological TransportStreptozotocinbiology.organism_classificationmedicine.diseaseRatsCholesterolEndocrinologyAcyltransferaseDietary Supplementsbiology.proteinlipids (amino acids peptides and proteins)Cholesterol EstersPhytotherapymedicine.drugLipoproteinJournal of Pharmacy and Pharmacology
researchProduct